Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS004 in advanced solid malignancies
NCT04278859Phase 1Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Apr 2020
- Primary completion
- Jul 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of tifcemalimab in solid tumor (advanced stage), sponsored by Shanghai Junshi Biosciences Co., Ltd. Started Apr 2020; status: completed.
02
Drugs
tifcemalimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04278859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04278859.